Not applicableStudy completedNCT05580016
What this trial is testing
Prognostic Value of Soluble Urokinase Plasminogen Activation Receptor (SUPAR) to Rule Out Complications in Patients Admitted in Emergency Department for Acute Abdominal Pain.
Who this might be right for
Soluble Urokinase Plasminogen Activation ReceptorAbdominal PainEmergency Department+1 more
Poitiers University Hospital 200